NASDAQ · IMNN
Healthcare · Biotechnology
$1.14
Up+$0.02 (+1.79%)
Updated Oct 8, 2026, 2:15 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · IMNN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
IMNN closed at $1.14 after 21 trading sessions, down 24.50% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $1.12 | $1.16 | $1.10 | $1.14 | 107.64K |
| Oct 6, 2026 | $1.24 | $1.2803 | $1.12 | $1.12 | 86.78K |
| Oct 5, 2026 | $1.30 | $1.32 | $1.22 | $1.24 | 82.72K |
| Oct 2, 2026 | $1.35 | $1.38 | $1.26 | $1.28 | 94.82K |
| Oct 1, 2026 | $1.29 | $1.3863 | $1.26 | $1.32 | 138.03K |
| Sep 30, 2026 | $1.28 | $1.33 | $1.28 | $1.29 | 127.44K |
| Sep 29, 2026 | $1.37 | $1.42 | $1.29 | $1.335 | 157.23K |
| Sep 28, 2026 | $1.43 | $1.44 | $1.3581 | $1.38 | 108.6K |
| Sep 25, 2026 | $1.34 | $1.4495 | $1.34 | $1.41 | 94.37K |
| Sep 24, 2026 | $1.44 | $1.445 | $1.30 | $1.35 | 184.08K |
| Sep 23, 2026 | $1.54 | $1.57 | $1.418 | $1.47 | 217.41K |
| Sep 22, 2026 | $1.43 | $1.59 | $1.43 | $1.51 | 331.34K |
| Sep 21, 2026 | $1.36 | $1.4741 | $1.35 | $1.43 | 117.03K |
| Sep 18, 2026 | $1.40 | $1.42 | $1.33 | $1.36 | 62.79K |
| Sep 17, 2026 | $1.41 | $1.4378 | $1.35 | $1.38 | 109.47K |
| Sep 16, 2026 | $1.40 | $1.48 | $1.38 | $1.41 | 73.35K |
| Sep 15, 2026 | $1.44 | $1.55 | $1.40 | $1.40 | 65.43K |
| Sep 14, 2026 | $1.49 | $1.53 | $1.41 | $1.465 | 84.32K |
| Sep 11, 2026 | $1.47 | $1.5301 | $1.42 | $1.47 | 129.44K |
| Sep 10, 2026 | $1.65 | $1.75 | $1.385 | $1.45 | 1.1M |
| Sep 9, 2026 | $1.54 | $1.5673 | $1.50 | $1.51 | 24.42K |
The latest Smart Investors Daily articles mentioning IMNN.
Company
Market Activity
Research & News
IMNN research
Company profile and research snapshot.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 17, 2026 | Maxim Group | Buy | — |
| May 19, 2025 | D. Boral Capital | Hold | — |
| May 13, 2025 | D. Boral Capital | Buy | — |
| May 7, 2025 | D. Boral Capital | Buy | — |
| Mar 26, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 1, 2026
By David Bautz, PhD NASDAQ: IMNN READ THE FULL IMNN RESEARCH REPORT Business Update R&D Day Highlights IMNN-001 in Advanced Ovarian Cancer On September 23, 2026, Imunon, Inc. (NASDAQ: IMNN) held an R&D Day to discuss the IMNN-001 program, which included a discussion on the use of localized IL-12 in cancer therapy, translational data that showed IMNN-001 is preferentially taken up by
Yahoo · Sep 29, 2026
Unique investment vehicle provides efficient access to equity capitalOutstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), (“IMUNON” or the “Company”), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together wi
SeekingAlpha · Sep 24, 2026
2026-09-24. The following slide deck was published by Imunon, Inc.
Yahoo · Sep 24, 2026
2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today is presenting an update on its
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IMNN.
